Navigation Links
New Interim Data About Combination Oral Contraceptives
Date:3/25/2011

WAYNE, N.J., March 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

Specifically, the new data provides healthcare providers with information regarding when the VTE risk associated with COCs is highest.  The risk of VTE is highest during the first year of COC use and the new data suggest that this increased risk is greatest during the first six months.  This risk is greatest when first starting the Pill and when restarting the same or a different Pill after a four week or greater break.  

The new data are from the ongoing, Long-Term Active Surveillance Study for Oral Contraceptives (LASS) – a large, multinational, prospective cohort, five-year follow-up safety study to the European Active Surveillance (EURAS) study. Cardiovascular events, including VTE, were the main clinical outcomes studied in LASS.   Together, these two studies will provide data for up to ten years on women using various COCs.  

"As a leader in women's contraception, we believe it is important for Bayer to take the lead in studying and communicating the risks and benefits of COCs," said Leo Plouffe, MD, Vice President, US Medical Affairs, Women's Healthcare, Bayer HealthCare Pharmaceuticals.  "The new information is helpful because while healthcare providers have long known about the risk of VTE associated with COCs, there was little information to indicate that there was an increased risk in women restarting COCs after a four week or greater period of non-use.  This new information should provide both healthcare providers and women who choose a COC for contraception with additional information when making the deci
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RPh, of Vernak Farms Pharmacy in Skaneateles, ... Roentsch Scholarship by the Professional Compounding Centers of America ... during PCCA,s International Seminar, held October 8-10, ... pharmacist and PCCA member who embodies the innovative and ... pharmacist in the compounding community. George ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... tissue processing company focused on cardiac and vascular surgery, ... President and Chief Executive Officer, has been elected to ... Steven G. Anderson , Executive Chairman ... has proven to be an excellent leader who is ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... Homeowners that are wondering how they can tell ... more. Clean Crawls gives 5 signs of poor ... it comes to insulation in their recently released article. ... Clean Crawls, can cause problems throughout your entire home. ... deteriorated, become damp, or been infested with pests should ...
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... Dotinga HealthDay Reporter FRIDAY, ... are developed that spot increased risks for certain cancers, one ... getting screened. But a new study suggests that, at ... who found out their genes doubled their risk of colon ... to get screened. "It didn,t make any difference, not ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... cancer patients with specific changes in the cancer genome ... after standard treatment compared to patients without these changes, ... 13 in the open-access journal PLoS Genetics . ... steps in the progression of the disease towards an ...
... (OTC Bulletin Board: VIVK) is the keynote presenting company ... International, Inc. ( www.regeneca.com ). The celebration ... of Regeneca International from across the United States. It ... in Newport Beach, California. Vivakor,s Chairman, Matt Nicosia ...
... Healthcare Trust of America, Inc. (the "REIT"), a ... of a Purchase and Sale Agreement (the "Agreement") to ... Carolina for approximately $16,250,000. The closing of the acquisition ... approximate 108,500 SF Mary Black Medical Office Building is ...
... Bioniche Pharma, a leading developer and manufacturer of ... (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP ... http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , "Bioniche Pharma is very ... injectable drugs," said Steve Thornton, Bioniche Pharma CEO. ...
... mice, pentamidine combats genetic defects that lead to myotonic dystrophy ... a drug used to treat pneumonia might serve as an ... tested the drug pentamidine in mice and found that it ... myotonic dystrophy, one of nine types of muscular dystrophy. The ...
... ... to educate people about ,bipolar disorder , , ... Wilmington, DE (PRWEB) November 11, 2009 -- As part of a panel ... firsthand by this disease. Debi was joined in New York by people living with ...
Cached Medicine News:Health News:Vivakor Presents at Nutraceutical Event 2Health News:Vivakor Presents at Nutraceutical Event 3Health News:Vivakor Presents at Nutraceutical Event 4Health News:Vivakor Presents at Nutraceutical Event 5Health News:Vivakor Presents at Nutraceutical Event 6Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 108,500 SF Medical Office Building Located in Spartanburg, South Carolina 2Health News:Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP 2Health News:Actress Debi Mazar Talks About her Family's Experience with Bipolar Depression 2Health News:Actress Debi Mazar Talks About her Family's Experience with Bipolar Depression 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: